Fluor completes Cell Therapy Launch Facility for Bayer

US-based engineering and construction firm Fluor Corporation has completed construction of pharmaceutical giant Bayer’s first global Cell Therapy Launch Facility in Berkeley, California.

A new state-of-the-art biopharmaceutical development and manufacturing facility that will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs, has been completed by Fluor. 

Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

Bayer’s new Global Cell Therapy Launch Facility. Photo: Bayer

“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”

Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.


Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.

Sign up

Andy Brown Editor, Editorial, UK - Wadhurst Tel: +44 (0) 1892 786224 E-mail: [email protected]
Neil Gerrard Senior Editor, Editorial, UK - Wadhurst Tel: +44 (0) 7355 092 771 E-mail: [email protected]
Catrin Jones Deputy Editor, Editorial, UK – Wadhurst Tel: +44 (0) 791 2298 133 E-mail: [email protected]
Eleanor Shefford Brand Manager Tel: +44 (0) 1892 786 236 E-mail: [email protected]